Structural mechanism of the pan‐BCR‐ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

T Zhou, L Commodore, WS Huang… - Chemical biology & …, 2011 - Wiley Online Library
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …
被引用次数：341 相关文章

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T Zhou, L Commodore, WS Huang, Y Wang… - Chemical Biology & …, 2010 - infona.pl
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

T Zhou, L Commodore, WS Huang… - … biology & drug …, 2011 - pubmed.ncbi.nlm.nih.gov
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance.

T Zhou, L Commodore, WS Huang… - Chemical Biology & …, 2011 - search.ebscohost.com
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T Zhou, L Commodore, WS Huang, Y Wang… - Chem. Biol. Drug …, 2012 - osti.gov
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

T Zhou, L Commodore, WS Huang, Y Wang… - Chemical Biology & …, 2010 - europepmc.org
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid
leukemia. However, drug resistance caused by kinase domain mutations has necessitated …

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T Zhou, L Commodore, WS Huang, Y Wang… - Chemical Biology & …, 2010 - cir.nii.ac.jp
抄録< jats: p> The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic
myeloid leukemia. However, drug resistance caused by kinase domain mutations has …